Fig. 1

SAC abrogation has different effects in EGFR TKI resistant clones. A Dose-response plots to AZD2811 (left), BAY1217389 (middle) and LY3295668 (right panels) of EGFR TKI-resistant clones derived from the PC9 cell line. Values shown are means ± SD of three independent experiments. In each experiment, every concentration of drug was tested in six wells (n = 6). B Cell cycle analysis of PC9-ER, PC9-GR3, PC9-GR4 and PC-GR4AZD1 clones. Cells were serum-starved for 24 h, FBS (10%) and AZD2811 (150 nM) or BAY1217389 (50 nM) were added, and cultures submitted to PI staining at the indicated times. S (green) and R (blue), clones sensitive and resistant to SAC abrogation. C Percentage of apoptotic/necrotic cells in PC9-ER, PC9-GR4, PC9-GR4 and PC-GR4AZD1 cultures. Cells were treated with AZD2811 (150 nM) or BAY1217389 (50 nM) and cultures submitted to annexin V/propidium iodide staining at the indicated times. Bars indicate mean ± SEM of two independent experiments. **p<0.01, *p<0.05 (Student’s t test). S (green) and R (blue), clones sensitive and resistant to SAC abrogation